These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

346 related items for PubMed ID: 36995604

  • 1. Exons 45-55 Skipping Using Antisense Oligonucleotides in Immortalized Human DMD Muscle Cells.
    He M, Yokota T.
    Methods Mol Biol; 2023; 2640():313-325. PubMed ID: 36995604
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Quantitative Antisense Screening and Optimization for Exon 51 Skipping in Duchenne Muscular Dystrophy.
    Echigoya Y, Lim KRQ, Trieu N, Bao B, Miskew Nichols B, Vila MC, Novak JS, Hara Y, Lee J, Touznik A, Mamchaoui K, Aoki Y, Takeda S, Nagaraju K, Mouly V, Maruyama R, Duddy W, Yokota T.
    Mol Ther; 2017 Nov 01; 25(11):2561-2572. PubMed ID: 28865998
    [Abstract] [Full Text] [Related]

  • 4. Biochemical characterization of patients with in-frame or out-of-frame DMD deletions pertinent to exon 44 or 45 skipping.
    Anthony K, Arechavala-Gomeza V, Ricotti V, Torelli S, Feng L, Janghra N, Tasca G, Guglieri M, Barresi R, Armaroli A, Ferlini A, Bushby K, Straub V, Ricci E, Sewry C, Morgan J, Muntoni F.
    JAMA Neurol; 2014 Jan 01; 71(1):32-40. PubMed ID: 24217213
    [Abstract] [Full Text] [Related]

  • 5. In vitro evaluation of novel antisense oligonucleotides is predictive of in vivo exon skipping activity for Duchenne muscular dystrophy.
    Wang Q, Yin H, Camelliti P, Betts C, Moulton H, Lee H, Saleh AF, Gait MJ, Wood MJ.
    J Gene Med; 2010 Apr 01; 12(4):354-64. PubMed ID: 20235089
    [Abstract] [Full Text] [Related]

  • 6. In Vitro Multiexon Skipping by Antisense PMOs in Dystrophic Dog and Exon 7-Deleted DMD Patient.
    Nakamura A, Aoki Y, Tsoumpra M, Yokota T, Takeda S.
    Methods Mol Biol; 2018 Apr 01; 1828():151-163. PubMed ID: 30171540
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Skipping multiple exons of dystrophin transcripts using cocktail antisense oligonucleotides.
    Echigoya Y, Yokota T.
    Nucleic Acid Ther; 2014 Feb 01; 24(1):57-68. PubMed ID: 24380394
    [Abstract] [Full Text] [Related]

  • 9. Quantitative Evaluation of Exon Skipping in Immortalized Muscle Cells In Vitro.
    Lim KRQ, Yokota T.
    Methods Mol Biol; 2018 Feb 01; 1828():127-139. PubMed ID: 30171538
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Optimizing antisense oligonucleotides using phosphorodiamidate morpholino oligomers.
    Popplewell LJ, Malerba A, Dickson G.
    Methods Mol Biol; 2012 Feb 01; 867():143-67. PubMed ID: 22454060
    [Abstract] [Full Text] [Related]

  • 13. Optimizing RNA/ENA chimeric antisense oligonucleotides using in vitro splicing.
    Takeshima Y, Yagi M, Matsuo M.
    Methods Mol Biol; 2012 Feb 01; 867():131-41. PubMed ID: 22454059
    [Abstract] [Full Text] [Related]

  • 14. Designing Effective Antisense Oligonucleotides for Exon Skipping.
    Shimo T, Maruyama R, Yokota T.
    Methods Mol Biol; 2018 Feb 01; 1687():143-155. PubMed ID: 29067661
    [Abstract] [Full Text] [Related]

  • 15. Bioinformatic and functional optimization of antisense phosphorodiamidate morpholino oligomers (PMOs) for therapeutic modulation of RNA splicing in muscle.
    Popplewell LJ, Graham IR, Malerba A, Dickson G.
    Methods Mol Biol; 2011 Feb 01; 709():153-78. PubMed ID: 21194027
    [Abstract] [Full Text] [Related]

  • 16. Contributions of Japanese patients to development of antisense therapy for DMD.
    Matsuo M, Takeshima Y, Nishio H.
    Brain Dev; 2016 Jan 01; 38(1):4-9. PubMed ID: 26094594
    [Abstract] [Full Text] [Related]

  • 17. Exon skipping quantification by quantitative reverse-transcription polymerase chain reaction in Duchenne muscular dystrophy patients treated with the antisense oligomer eteplirsen.
    Anthony K, Feng L, Arechavala-Gomeza V, Guglieri M, Straub V, Bushby K, Cirak S, Morgan J, Muntoni F.
    Hum Gene Ther Methods; 2012 Oct 01; 23(5):336-45. PubMed ID: 23075107
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Antisense oligonucleotide-induced exon skipping restores dystrophin expression in vitro in a canine model of DMD.
    McClorey G, Moulton HM, Iversen PL, Fletcher S, Wilton SD.
    Gene Ther; 2006 Oct 01; 13(19):1373-81. PubMed ID: 16724091
    [Abstract] [Full Text] [Related]

  • 20. Dystrophin quantification and clinical correlations in Becker muscular dystrophy: implications for clinical trials.
    Anthony K, Cirak S, Torelli S, Tasca G, Feng L, Arechavala-Gomeza V, Armaroli A, Guglieri M, Straathof CS, Verschuuren JJ, Aartsma-Rus A, Helderman-van den Enden P, Bushby K, Straub V, Sewry C, Ferlini A, Ricci E, Morgan JE, Muntoni F.
    Brain; 2011 Dec 01; 134(Pt 12):3547-59. PubMed ID: 22102647
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.